An FDA-approved medication can now treat Friedreich's ataxia, but health plan barriers and formulary exclusions keep many patients from receiving it.

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

Jupiter Neurosciences (JUNS) issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product ...

Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of chief ...

Detailed price information for Jupiter Neurosciences Inc (JUNS-Q) from The Globe and Mail including charting and trades.

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended by the EMA’s human ...

The 200-page journal includes an article about the massacre on Dunlavin green in 1798, and other articles on Hollywood, ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Alongside public hearings on Bill 83 to promote the practice of medicine within the public health and social services network, which begin tomorrow, the Point St. Charles Community Clinic and its ...